G1 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021

Rhea-AI Summary

G1 Therapeutics, a clinical-stage oncology company, announced that CEO Jack Bailey will present a company update at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 2:50 p.m. ET. The presentation will be accessible via a live and archived webcast on the company’s events page. G1 Therapeutics focuses on developing therapies to improve cancer treatment outcomes, including Trilaciclib, which is under FDA review with a PDUFA action date of February 15, 2021, and Rintodestrant, aimed at treating ER+ breast cancer.

RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Jack Bailey will present a company update at the 39^th Annual J.P. Morgan Healthcare Conference on January 13, 2021 at 2:50 p.m. ET.

To access the live and archived webcast of the presentation, please visit the Events & Presentations page of the G1 website.

About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. The company is developing and advancing two novel therapies. Trilaciclib is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy. Trilaciclib received Breakthrough Therapy Designation and is under review by the U.S. Food and Drug Administration (FDA) with a PDUFA action date of February 15, 2021. Rintodestrant is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer.

G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contact:
Will Roberts
G1 Therapeutics, Inc.
Vice President, Investor Relations & Corporate Communications
610-304-5882
wroberts@g1therapeutics.com

FAQ

What will the CEO of G1 Therapeutics present at the J.P. Morgan Healthcare Conference?

CEO Jack Bailey will present a company update at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021.

When is the G1 Therapeutics presentation scheduled?

The G1 Therapeutics presentation is scheduled for January 13, 2021, at 2:50 p.m. ET.

How can I access the G1 Therapeutics conference presentation?

The presentation can be accessed via a live and archived webcast on the G1 Therapeutics events page.

What drug is G1 Therapeutics developing for chemotherapy patients?

G1 Therapeutics is developing Trilaciclib, which is designed to improve outcomes for patients undergoing chemotherapy.

What is the PDUFA action date for Trilaciclib?

The PDUFA action date for Trilaciclib is February 15, 2021.